Target Preparations in Ovarian Cancer Therapy

World science does not stop attempts to improve the effectiveness of malignant ovary neoplasms treatment, taking into account the fact that this pathology mortality rate takes the steady first place in cancer gynecology. The search for screening and early diagnosis algorithms, as well as the surgical improvement in this type of tumor treatment continues. Thanks to molecular biology innovations, there are significant advances in understanding the etiology and pathogenesis of the disease. In this regard, the main interest of researchers is in studying and developing new drugs that can not only improve the effectiveness of treatment, but also do not reduce the life quality of this category of patients. It should be noted that the life quality indicator in modern oncology is in line with the survival rate and is one of the main criteria for assessing the treatment effectiveness. Over the past half century, there have occurred a number of revolutionary changes in drug therapy of one of the most insidious malignant neoplasms in the female genecology. The main cornerstones in the progression of ovarian cancer chemotherapy are related to the introduction of platinum series drugs to the routine practice, and then taxol. Today, there is an active search for targets for applying new generation drugs, the so-called target drugs, which damage tumor structures directly. The article summarizes the latest world experience of using various types of targeted drugs in ovarian cancer treatment. The author suggests a detailed analysis of several major recent world-wide randomized clinical studies of using various groups targeting agents in the combined and integrated treating common forms of ovarian cancer. The article clearly outlines the advantages and disadvantages of using each studied drugs on the examples of the results obtained during clinical application. A comparative analysis of their application is presented in monorail, as well as in combinations with well-known and widely used drugs for ovarian cancer chemotherapy. The author notes that the most effective and of the studied targeted drugs is bevacizumab. The article also points out that it has been successfully used for several years in ovarian cancer treatment. The present review does not pretend to fully reflect the situation in preclinical and clinical trials of antitumor drugs for ovarian cancer. All the drugs are united by the presence of a specific molecular target in the tumor cell. No one doubts that the future of clinical oncology is associated with a personalized approach and depends on the definition of molecular genetic characteristics of the tumor. The first steps in this direction are taken in ovarian cancer treatment. At present, several works based on a large number of observations have been published in the world. They identify 6 molecular subtypes of ovarian cancer. All of the above mentioned suggests that understanding of molecular genetics mechanisms and the identification of targets are increasingly necessary in routine clinical practice for the personalized selection of therapy and the determination of its effectiveness, which, in turn, becomes the main trend in ovarian cancer treatment improving.